<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766895</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-980083</org_study_id>
    <secondary_id>100CM-KMU-09</secondary_id>
    <nct_id>NCT01766895</nct_id>
  </id_info>
  <brief_title>Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan</brief_title>
  <official_title>Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The linkage between viral hepatitis and renal failure is complex. The current study aims to
      exlore the long-term prevalence of viral hepatitis among uremic patients in Taiwan
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are prospectively recruited from 15 hemodialysis units including one medical center,
      3 satellite hospitals and 11 local clinics in Taiwan. Patients who provided informed consents
      for blood tests including genetic study related to HCV spontaneous seroclearance are enrolled
      for analysis. All the eligible subjects are tested for both HCV antibodies (third-generation,
      enzyme immunoassay; Abbott Laboratories, North Chicago, IL) and hepatitis B surface antigen
      (HBsAg). HCV RNA is tested by polymerase chain reaction (Cobas Amplicor Hepatitis C Virus
      Test, V.2.0; Roche Diagnostics, Branchburg, New Jersey, USA; detection limit: 50 IU/ml) twice
      for at least 6 months apart if anti-HCV is positive to ensure chronicity of HCV infection.
      HBsAg is quantified with the use of a standard quantitative chemiluminescent microparticle
      immunoassay (ARCHITECT HBsAg, Abbott Diagnostics). The concentration of HBsAg in the specimen
      is determined using a previously generated Architect HBsAg calibration curve (range, 0.05-250
      IU/mL). Samples with serum HBsAg titer &gt;250 IU/mL were diluted at 1:20 and 1:500 with the
      Architect HBsAg diluent and retested to expand the upper limit of the dynamic range from 250
      to 125,000 IU/mL. Serum HBV DNA is determined by a standardized automated quantitative PCR
      assay (Cobas Amplicor HBV Monitor; Roche Diagnostics; detection limit 200 copies/ml) if
      patients are seropositive for HBsAg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>seroprevalence of viral hepatitis in uremic patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>factors associated with HCV clearance or reappearance</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>HBV seroconversion</measure>
    <time_frame>10 years</time_frame>
    <description>Factors assocaited with HBV seroconversion</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Uremia</condition>
  <condition>Viral Hepatitis</condition>
  <arm_group>
    <arm_group_label>uremic patients</arm_group_label>
    <description>blood sampling of viral hepatitis in uremic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>blood sampling of viral hepatitis to determined seroprevalence in uremic patients</description>
    <arm_group_label>uremic patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      host factors ssociated with viral hepatitis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Uremic patients will recruited from 15 hemodialysis units including one medical center, 3
        satellite hospitals and 11 local clinics in Taiwan.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  uremic patients

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung-Feng Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Feng Huang, MD</last_name>
      <phone>88673121101</phone>
      <phone_ext>7475</phone_ext>
      <email>fengcheerup@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chung-Feng Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Lung Yu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uremia</keyword>
  <keyword>HBV</keyword>
  <keyword>HCV</keyword>
  <keyword>seroclearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Uremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

